p21-Expressing Monocyte Therapy for Macrophage PrCR Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as those targeting immune checkpoints like CTLA-4 and PD-1, have limitations in effectively addressing macrophage-mediated programmed cell removal (PrCR) of tumor cells, necessitating a deeper understanding of immunoregulation for more effective cancer therapies.
Innovation Solution
The use of monocytes overexpressing the cyclin-dependent kinase inhibitor p21 protein, through genetic modification with recombinant vectors, to enhance macrophage PrCR and transition to a pro-inflammatory phenotype, thereby increasing the immune system's ability to recognize and destroy tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune checkpoint inhibitors (CTLA-4, PD-1) are used to treat cancer, then adaptive immune response is enhanced, but macrophage-mediated programmed cell removal (PrCR) of tumor cells is not effectively addressed
Solution Approach 1:
The patent introduces p21 as a molecular intermediary that bridges macrophage activation and tumor cell phagocytosis. By overexpressing p21 in monocytes before adoptive transfer, the invention creates a mediator that enhances macrophage-mediated PrCR of tumor cells, addressing the gap left by conventional checkpoint inhibitors that do not effectively target macrophage function.
2Reliability
If monocytes are genetically modified to overexpress p21 protein, then macrophage PrCR and pro-inflammatory phenotype are enhanced, but treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by genetically modifying monocytes ex vivo to overexpress p21 before adoptive transfer into patients. This pre-modification ensures that the cells arrive at the target site already equipped with enhanced PrCR capability, eliminating the need for complex in vivo manipulation and simplifying the overall treatment protocol while maintaining high efficacy.
3Reliability
If p21 overexpressing monocytes are adoptively transferred, then cancer progression is delayed and survival is improved, but deeper understanding of immunoregulation is required
Solution Approach 1:
The patent establishes a feedback mechanism where p21 overexpression in adoptively transferred monocytes leads to enhanced macrophage activation and tumor cell clearance. The observed delay in cancer progression and improvement in survival provide feedback that validates the approach, while the mechanism itself (p21-mediated macrophage activation) offers a measurable pathway for understanding immunoregulation without requiring complete elucidation of all underlying molecular interactions.
Data Source
AI summary
Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.